UNSPSC 51272114: Parethoxycaine hydrochloride

This classification denotes an anesthetic agent with the molecular formula C15H23NO3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 414P5USJ7F, chemically known as benzoic acid, p-ethoxy-, 2-(diethylamino)ethyl ester, hydrochloride but more generally known as parethoxycaine hydrochloride, which bears US NIH Compound Identifier 8694. European Medicines Agency schedules Parethoxycaine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14777MIG.

UNSPSC 51272114 Parethoxycaine hydrochloride is a Commodity code, but the recent state and local opportunities posted under it do not reflect procurement of parethoxycaine or any local anesthetic pharmaceutical matching that specification. The code shows little relevant recent activity aligned with its nominal scope.

The three most recent state and local opportunities tagged to this code involve broader pharmaceutical and medical supply procurement: Seminole County, Florida issued an IFB on June 30, 2026 (due July 26, 2026) for naloxone and drug deactivation systems purchased annually; the Texas Health and Human Services Commission issued an RFI on April 3, 2026 regarding direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP due March 26, 2026 for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities. None of these solicitations target parethoxycaine hydrochloride or drugs in that therapeutic category. The mismatch between the code's stated scope and the actual work being solicited suggests either miscoding of opportunities or a lack of genuine market demand for this specific pharmaceutical under the UNSPSC category at the state and local level.